Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial

Feng‐Hua Wang(Sun Yat-sen University), Rui‐Hua Xu(Sun Yat-sen University), Zengqing Guo(Fujian Provincial Cancer Hospital), Lu Wen(Union Hospital), Zuoxing Niu(Shandong Tumor Hospital), Feng Bi(Tianjin University of Traditional Chinese Medicine), Yong Tang(Chongqing Medical University), Wei Wang(Wellcome Sanger Institute), Jin Yan(Sichuan Cancer Hospital), Bing Hu(Zhejiang University of Science and Technology), Guanghai Dai(Chinese PLA General Hospital), Shujun Yang(First Affiliated Hospital of Xi'an Jiaotong University), Min Tao(Shanghai East Hospital), Yanhong Deng(Sun Yat-sen University), Liangjun Zhu, Suzhan Zhang(Zhejiang Cancer Hospital)
Chinese Journal of Cancer Research
January 1, 2021
10.21147/j.issn.1000-9604.2021.04.06
Cited by 11

Related Papers

Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma
|Molecular Cancer|2019|868
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701